Jeffrey Lamar Ledbetter

US Patent:

20020031510, Mar 14, 2002

Filed:

May 22, 2001

Appl. No.:

09/862255

Inventors:

Christian Larsen - Atlanta GA, US
Alejandro Aruffo - Belle Mead NJ, US
Diane Hollenbaugh - Newtown PA, US
Peter Linsley - Seattle WA, US
Jeffrey Ledbetter - Seattle WA, US
Thomas Pearson - Atlanta GA, US

Assignee:

Bristol-Myers Squibb Company

International Classification:

A61K039/395

US Classification:

424/131100, 424/144100

Abstract:

The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.

US Patent:

20050202011, Sep 15, 2005

Filed:

Jan 4, 2005

Appl. No.:

11/028793

Inventors:

Christian Larsen - Atlanta GA, US
Alejandro Aruffo - Edmonds WA, US
Diane Hollenbaugh - Seattle WA, US
Peter Linsley - Seattle WA, US
Jeffrey Ledbetter - Seattle WA, US
Thomas Pearson - Atlanta GA, US

International Classification:

A61K039/395

US Classification:

424144100

Abstract:

The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.

US Patent:

20090186037, Jul 23, 2009

Filed:

Sep 10, 2008

Appl. No.:

12/207997

Inventors:

Christian P. Larsen - Atlanta GA, US
Alejandro A. Aruffo - Sudbury MA, US
Diane L. Hollenbaugh - Seattle WA, US
Peter S. Linsley - Seattle WA, US
Jeffrey A. Ledbetter - Seattle WA, US
Thomas C. Pearson - Atlanta GA, US

International Classification:

A61K 39/395
A61K 38/16
A61P 37/06

US Classification:

4241441, 514 12

Abstract:

The present invention provides a method for inhibiting an immune response and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.

US Patent:

59165600, Jun 29, 1999

Filed:

Mar 20, 1997

Appl. No.:

8/821400

Inventors:

Christian P. Larsen - Atlanta GA
Alejandro A. Aruffo - Edmonds WA
Diane L. Hollenbaugh - Seattle WA
Peter S. Linsley - Seattle WA
Jeffrey A. Ledbetter - Seattle WA
Thomas C. Pearson - Atlanta GA

Assignee:

Bristol-Myers Squibb Company - Pinceton NJ
Emory University - Atlanta GA

International Classification:

C07K 1628

US Classification:

4241541

Abstract:

The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.